1 The donor injury rate for allogeneic whole blood donations is 0.011% (same ARC database) to 0.014%.
Infusion-related adverse reactions associated with cord blood (CB) transplants are considered to be less frequent and less severe when compared to cryopreserved marrow or peripheral blood stem cells. 1 The true incidence of these reactions is unknown, although it is reported that 30% to 60% of CB recipients are affected by infusion reactions. 1, 2 Recently, there have been six published reports of severe, life-threatening cardiopulmonary reactions associated with CB infusions (Table 1) . 3, 4 A review by the National Marrow Donor Program (NMDP) and the Food and Drug Administration (FDA) of 13 serious CB-associated infusion reactions events showed that the majority of cases (92%; 12/13) involved infusion of at least one red blood cell (RBC)-replete CB unit. 3 As a consequence, the NMDP and FDA provided recommendations for thawing and washing RBC-replete CB units. 3 We report a case of a seventh cardiopulmonary reaction associated with the infusion of a RBC-depleted, CB unit diluted with human serum albumin (HSA)-dextran 40. 2 The patient was a 16-year-old, 46-kg, group O Caucasian female with acute biphenotypic leukemia. As part of a clinical trial, the patient was randomly assigned to receive a five of six HLA-matched, double-CB transplant (Table 1) . Both CB units were RBC-depleted and cryopreserved in a solution containing 10% dimethyl sulfoxide DMSO and 10% dextran 40. After being thawed, both CB units were diluted 1:3 with 5% HSA-8% dextran 40 solution, for a combined final infusion volume of 411 mL and less than 3% DMSO per unit. The total transplant dose was 2.6 ¥ 10 5 CD34/kg and 5.7 ¥ 10 7 total nucleated cells/kg recipient weight.
The patient was medicated before transfusion with acetaminophen, diphenhydramine, hydrocortisone, and mannitol per institutional clinical practice guidelines. Less than 5 minutes after starting the first CB unit, the patient experienced a severe anaphylactic reaction characterized by nausea, vomiting, dyspnea, wheezing, chest tightness, tachycardia, and tachypnea. The infusion was immediately stopped and the patient was treated with hydrocortisone, diphenhydramine, lorazepam, ipratropium, and albuterol and placed on 4 L of oxygen by nasal cannula. After 10 minutes, the patient's symptoms improved and the infusion of CB Unit 1 was slowly restarted and subsequently completed within 60 minutes. After additional pretransfusion medication, the patient received the second CB unit over 60 minutes. The second infusion was uneventful except for hypertension and a few hives 2 hours postinfusion. Both were successfully treated with additional antihistamine and antihypertensive medications.
Diagnostic studies at the time of the infusion reaction showed a prolonged QTc (baseline, 0.416-0.514 sec) and elevated troponin (baseline, <0.01-1.7 ng/mL) and B-type natriuretic peptide (baseline, 110-592 pg/mL). An echocardiogram revealed regional hypokinesis of the basal half of the posterior two-thirds of the septum, with overall mildly depressed left ventricular systolic function. The patient had no evidence of electrolyte abnormalities, renal insufficiency, intravascular hemolysis, or acute pulmonary changes. Pertinent EKG and laboratory studies returned to baseline within 48 hours and were attributed to transient myocardial ischemia.
Our patient's symptoms were consistent with a severe, anaphylactic reaction. We believe that the reaction was precipitated by dextran 40. Acute, severe reactions to dextran 40 have a reported incidence of 1 in 2000 and can be associated with cardiac ischemia and pulmonary and renal injury. 4, 5 It is noteworthy that the majority (six of seven) of cardiopulmonary infusion reactions reported to date were associated with CB units frozen and/or diluted in HSA-dextran. As observed by Ma and colleagues 4 reports of severe CB infusion reactions "coincide with the introduction of dextran in cryopreservation" and include more recent protocols for dilution or washing CB products in HSA-dextran. 2 Ongoing investigations into severe CB reactions should include the potential role of dextran in such reactions, as well as possible prophylaxis with dextran-1, a hapten known to significantly decrease the risk of dextran reactions. 
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Isoimmune neonatal neutropenia in a North
African newborn due to anti-Fcg RIIIb_ 3434 208.. 212 Human Fcg RIIIb (FcgRIIIb; CD16) is a low-affinity Fc receptor for immunoglobulin (Ig)G1 and IgG3, constitutively expressed with a high density (100,000 to 400,000 copies per cell), only by granulopoietic cells. 1 The human neutrophil antigens HNA-1a, HNA-1b, and HNA-1c, encoded by the FcgRIIIb gene, are polymorphic forms of this receptor. 2 Alloantibodies directed against these antigens can be responsible for neonatal alloimmune neutropenia, transfusion-related acute lung injury, and autoimmune neutropenia. Few people (approx. 1 of 1000 individuals of European origin) lack the FcgRIIIb gene and present the HNA-1 null phenotype (FcgRIIIb deficiency).
3 During pregnancy, women lacking this gene, and subsequently the protein, can produce CD16 isoantibodies able to cross the placenta and cause transient isoimmune neonatal neutropenia (INN). 4, 5 We report a case of INN due to an anti-FcgRIIIb in a mother with FcgRIIIb deficiency. A 25-year-old mother from North Africa prematurely delivered a female newborn at 33 weeks of gestation (body weight, 2300 g), due to early labor. The two previous pregnancies were free of complications and the newborns were healthy. In this case, systematic newborn blood screening showed severe neutropenia (200 ¥ 10 6 neutrophils/L) and hypocalcemia (1.94 mmol/L) on the first day of life with no other clinical or biologic abnormalities. No complication was observed in the child 
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and, without any treatment, the neutrophil count spontaneously increased to 600 ¥ 10 6 /L on Day 18 and 1800 ¥ 10 6 /L after 1 month, when she was discharged from the hospital. Neonatal alloimmune neutropenia was suspected and laboratory tests were performed on maternal and newborn blood samples obtained immediately after delivery.
IgG anti-granulocyte antibodies were detected in maternal serum by means of a strongly positive granulocyte immunofluorescence test (GIFT), but not by the granulocyte agglutination test (GAT) even after sera dilution (to 1/2 to 1/512). A high level of anti-CD16 was identified by monoclonal antibody immobilization of granulocyte antigen assay. Granulocyte antibodies were also found in the newborn by GIFT. Maternal neutrophils were typed as CD16 negative with the GAT using polyclonal antibodies. HNA-1 genotyping was performed by polymerase chain reaction-sequence specific primers (PCR-SSP). The newborn was found negative for HNA-1a and HNA-1c, but positive for HNA-1b, whereas the mother was negative for HNA-1a, -1b, and -1c, consistent with an FcgRIIIb deficiency (Fig. 1) .
Our observation confirms the risk for a mother with FcgRIIIb deficiency to produce CD16 isoantibodies, which can be responsible for INN. To the best of our knowledge, no FcgRIIIb deficiency has been reported in people originating from North Africa. It is known that the HNA-1 null phenotype is more frequent in Africans (1%-2%) than in Caucasians (0.15%) and nearly absent in Asians and Amerindians. 6 Interestingly, this rare null phenotype has been found in 0.8% of Spanish blood donors, which may be related to their berberian origin. 7 Paradoxically, as in our patient, most of the FcgRIIIb-deficient individuals do not suffer from repeated infections or autoimmune or immune complex diseases, while this receptor contributes to the phagocytosis of opsonized microorganisms and the clearance of immune complex from the circulation. 8 Further investigations are required to explain the absence of immune consequences in individuals carrying this rare phenotype. 1 The donor injury rate for allogeneic whole blood donations is 0.011% (same ARC database) to 0.014%. 1 Overwhelmingly, the injuries are minor, but there can be severe injuries such as fractures, lacerations, and closed head injuries.
It seems intuitive that the risk of donor injury would be the same for all donors who progress to syncope. This hypothesis was tested by analyzing 30.2 million allogeneic whole blood donations to the American Red Cross over a 5-year period (same ARC database). The syncope and donor injury rates at the collection sites were evaluated. The overall donor syncope and injury rates were 0.13% (39,392/30,190,815) and 0.011% (3462/30,190,815), respectively, and a donor injury occurred in 8.8% of the syncopal episodes.
The proportion of syncopal episodes associated with donor injuries was evaluated by age interval for donations by all donors, first-time female donors, repeat female donors, first-time male donors, and repeat male donors (Table 1) . For each of these donor groups, the baseline interval was defined as the interval, among all intervals with at least 40 donor injuries, that had the lowest proportion. The ratio of the proportion for each interval to the proportion for the baseline-that is, the relative risk-was calculated. The proportions and relative risks were also evaluated for all donors grouped by sex and donation status (first-time vs. repeat donation). Table 1 shows that for all donations, the proportion of syncopal episodes associated with injuries is highest in 16-year-old donors, decreases with increasing age, and begins to plateau in the 29-to 42-year-old age group. Relative risks are increased in 16-, 17-, 18-, and 19-year-olds by 125, 96, 72, and 39%, respectively. The same pattern is observed in first-time and repeat female donors and also in first-time male donors but not in repeat male donors. Donor injury rates after syncope were 17% higher in females ( These findings show that donor injury rates after syncope are greatly increased in very young donors and also increased, but to a much lesser degree, in females and first-time donors. A study of the character of syncopal reactions in very young donors and older donors might explain why the rates of donor injuries after syncope differ with age. A better understanding of syncope could potentially help us to improve safety for donors.
